The P2Y 12 receptor (P2Y 12 R), one of eight members of the P2YR family expressed in humans, is one of the most prominent clinical drug targets for inhibition of platelet aggregation. Although mutagenesis and modelling studies of the P2Y 12 R provided useful insights into ligand binding [1] [2] [3] [4] , the agonist and antagonist recognition and function at the P2Y 12 R remain poorly understood at the molecular level.
The P2Y 12 receptor (P2Y 12 R), one of eight members of the P2YR family expressed in humans, is one of the most prominent clinical drug targets for inhibition of platelet aggregation. Although mutagenesis and modelling studies of the P2Y 12 R provided useful insights into ligand binding [1] [2] [3] [4] , the agonist and antagonist recognition and function at the P2Y 12 R remain poorly understood at the molecular level.
Here we report the structures of the human P2Y 12 R in complex with the full agonist 2-methylthio-adenosine-59-diphosphate (2MeSADP, a close analogue of endogenous agonist ADP) at 2.5 Å resolution, and the corresponding ATP derivative 2-methylthio-adenosine-59-triphosphate (2MeSATP) at 3.1 Å resolution. These structures, together with the structure of the P2Y 12 R with antagonist ethyl 6-(4-((benzylsulfonyl) carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) 5 , reveal striking conformational changes between nucleotide and nonnucleotide ligand complexes in the extracellular regions. Further analysis of these changes provides insight into a distinct ligand binding landscape in the d-group of class A G-protein-coupled receptors (GPCRs). Agonist and non-nucleotide antagonist adopt different orientations in the P2Y 12 R, with only partially overlapped binding pockets. The agonist-bound P2Y 12 R structure answers long-standing questions surrounding P2Y 12 R-agonist recognition, and reveals interactions with several residues that had not been reported to be involved in agonist binding. As a first example, to our knowledge, of a GPCR in which agonist access to the binding pocket requires large-scale rearrangements in the highly malleable extracellular region, the structural and docking studies will therefore provide invaluable insight into the pharmacology and mechanisms of action of agonists and different classes of antagonists for the P2Y 12 R and potentially for other closely related P2YRs.
After sensing their endogenous extracellular ligands, GPCRs activate associated intracellular signal transduction pathways that subsequently lead to physiological responses 6 . Structures of five GPCRs (rhodopsin 7, 8 , b 1 (b 1 AR) 9, 10 and b 2 adrenergic receptors (b 2 AR) 11, 12 , A 2A adenosine receptor (A 2A AR) 13, 14 and M2 muscarinic receptor 15, 16 ) have now been determined in both antagonist-and agonist-bound states. Each of these five receptors, however, belong to the a-group of class A GPCRs 17 . Here we describe a 2.5 Å structure of human P2Y 12 R bound to the full agonist 2MeSADP, and a 3.1 Å structure of P2Y 12 R bound to a potential partial agonist 2MeSATP (Extended Data Table 1 ). Together with the 2.7 Å structure of P2Y 12 R bound to the antagonist AZD1283 reported in the accompanying paper 5 , this allows the first crystallographic assessment of a receptor with both agonist-and antagonist-bound structures in the d-group of class A GPCRs.
All three P2Y 12 R structures were determined using the same thermostabilizing construct 5 . The receptor conformations of the 2MeSADP and 2MeSATP bound complexes are very similar (Ca root mean squared deviation (r.m.s.d.) 5 0.6 Å ), and both ligands overlay well in the same binding pocket (r.m.s.d. of common atoms 5 0.6 Å ), with the c-phosphate group of 2MeSATP extended towards the extracellular surface ( Fig. 1 and Extended Data Fig. 1 ). As the two structures are similar, we will focus our discussions mainly on the higher resolution P2Y 12 R-2MeSADP structure, mentioning the specific differences of the 2MeSATP-bound complex when relevant.
The receptor is folded into a canonical seven transmembrane (7TM) bundle with a partially resolved intracellular helix VIII (Fig. 1) . The straight conformation and tilted orientation of helix V observed in the AZD1283-bound structure 5 is probably a genuine structural feature inherent to the P2Y 12 R, as it is consistent in all three structures despite the different crystal packing configurations (Extended Data Fig. 2 ). Both disulphide bonds, bridging the amino terminus (C17) with helix VII (C270 7.25 , superscript indicates Ballesteros-Weinstein residue numbering 18 ) and the highly conserved disulphide bond between helix III (C97 3.25 ) and extracellular loop 2 (ECL2, C175) are observed.
Comparison of the P2Y 12 R-AZD1283 and P2Y 12 R-2MeSADP complex structures reveals remarkable differences. The largest conformational change occurs in helices VI and VII. The extracellular part of helix VI in the 2MeSADP-bound structure shifts over 10 Å and helix VII over 5 Å towards the axis of the 7TM helical bundle, as compared to the antagonist-bound structure (Fig. 2) . In the AZD1283-bound structure, the phenyl moiety of the antagonist apparently prevents this inward movement of helix VI, which may explain the difference between the two complexes. The inward shift of helices VI and VII in the 2MeSADP complex allows formation of an extensive ionic and polar interaction network with the phosphate groups of 2MeSADP. Connected by a disulphide bond to helix VII, the N terminus is moved towards the axis of the helical bundle as well; the position of R19, for example, shifts by ,6.6 Å with agonist bound. Compared with the structure of the antagonistbound protease-activated receptor 1 (PAR1, also known as F2R, the receptor with the closest sequence homology and known structure to P2Y 12 R) 19 , the largest differences are observed in the straight versus bent conformation of helix V, as well as in the positions of the extracellular parts of helix VI, which in PAR1 adopts an intermediate conformation between the agonist-and antagonist-bound P2Y 12 R structures (Extended Data Fig. 3 ).
All ECLs have clear density and are resolved in the agonist-bound structure, whereas only ECL3 was resolved in the P2Y 12 R-AZD1283 complex structure. The highly conserved C97 3.25 -C175 ECL2 disulphide bond stabilizing the conformation of ECL2 is clearly observed in the agonist-bound structure, although it was not resolved with antagonist bound 5 . Formation of this disulphide bond in the P2Y 12 R-2MeSADP complex requires an unwinding of the helical bulge structure in the extracellular portion of helix III that comprises ,4.6 residues instead of the ,3.6 residues in a regular a-helical turn. As a result, there is a Ca rotation of C97 3.25 along the helical path by over 60u, and a relocation of other residues at this region as compared with the AZD1283 complex (Extended Data Fig. 4 ). In addition to the structural changes of helix III, the extracellular tip of helix V is also shifted ,2 Å towards the helical bundle to satisfy formation of this disulphide bond (Fig. 2b) .
With these substantial rearrangements of the helical bundle, ECLs and the N terminus, the agonist-bound structure appears to be much tighter compared with the antagonist-bound structure, with 2MeSADP almost completely enclosed in the receptor. A trend for slight contraction of the ligand binding pocket was observed for some a-group GPCRs in agonist-bound as compared to antagonist-bound structures [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , though these extracellular rearrangements are of unprecedented scale in the P2Y 12 R. This very high plasticity of the extracellular region in the P2Y 12 R may help to explain how rather bulky nucleotide ligands gain access into the binding cavity, which is completely covered by loops and N-terminal residues (Fig. 1c) . A high plasticity in the ECL region was also proposed for another d-group GPCR, PAR1 (ref. 19 ), but the current availability of only an antagonist-bound PAR1 structure precludes crystallographic description of those changes.
Interestingly, the intracellular conformational changes of P2Y 12 R are less prominent than those at the extracellular side (Fig. 2b, c) . In both P2Y 12 R structures the intracellular half of the 7TM domain has a very similar conformation to that observed in the PAR1 structure (Extended Data Fig. 3c ). Only minor changes in helices VI and VII were observed in the intracellular part of P2Y 12 R-2MeSADP. They do not appear consistent, however, with large changes in helical positions observed in the intracellular region in active state agonist-bound A 2A AR, or b 2 AR stabilized by G-protein 12, 14 . It is therefore likely that the P2Y 12 R-2MeSADP structure represents an agonist-bound inactive state with respect to the intracellular region, similar to the one observed in agonist-bound b 1 AR and b 2 AR without G-protein or a G-protein mimic stabilizing their active state 10, 20 . The rearranged 2MeSADP-binding pocket consists of residues from helices III, IV, V, VI and VII as in the P2Y 12 R-AZD1283 structure 5 , but also extensively involves ECL2 and the N terminus. Both pockets described in the P2Y 12 R-AZD1283 structure are still present, although contracted, especially pocket 1, due to the inward movement of helices VI and VII (Extended Data Fig. 5 ). In particular, the inward shift of helix VI in the agonist-bound structure shrinks pocket 1 substantially so that it would preclude AZD1283 binding. As a result, although both 2MeSADP and AZD1283 bind to the same pocket, their orientations are completely different, with only partial overlap between them (Fig. 3) .
The adenine group of 2MeSADP occupies the same aromatic binding site as the nicotinate group in AZD1283, forming a similar p-p interaction with the Y105 3.33 side chain. The 2-thioether inserts into a hydrophobic pocket formed by F106 3.34 , L155 4.56 , S156
4.57 and N159 4.60 , and serves as an anchor to maintain the adenine core and the ribose ring in an optimal orientation (Extended Data Fig. 5a ). Thus, 2MeSADP binds with greater complementarity, which explains the higher affinity of this ligand compared with ADP. The 2-thioether and amino groups of adenine overlay with the ethyl ester and cyano substituents on the nicotinate group (Fig. 3b) . The orientation of the ribose moiety corresponds to that of the methyl group on the nicotinate moiety. The ribose 29 and 39 hydroxyl groups interact with K179 ECL2 and H187 5.36 and with T163 ECL2 and K179
ECL2
, respectively. The interactions between the receptor and the diphosphate of 2MeSADP involve numerous hydrophilic and positively charged residues (Fig. 3c) . As predicted on the basis of the sequence analysis and confirmed through mutagenesis [21] [22] [23] , two essential cationic residues R256
6.55 and K280 7.35 (Extended Data Table 2 ) and an aromatic residue Y259 6 .58 that is conserved 
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in the P2Y 12 R-like subfamily coordinate phosphate moieties. In addition to these residues, a residue not previously implicated in agonist binding, the third cationic residue R93 3.21 , contacts the b-phosphate. Three water molecules also bridge the interaction between b-phosphate with a fourth cationic residue, R19 (N terminus). Some residues that are thought to participate in agonist binding, however, have no direct contact with the nucleotide ligands. The R265 ECL3 side chain, which was previously implicated in activation of the receptor 23 , is positioned away from 2MeSADP. Interestingly, the conserved K174
ECL2
, which was previously predicted to interact with 2MeSADP 22, 24 , does not form a direct contact with the agonist, but forms a salt bridge to E273 7.28 that apparently helps to stabilize the agonist-bound conformation.
Cysteine residues forming the conserved disulphide bond are also involved directly in the binding of 2MeSADP. The main chain carbonyl of C97
3.25 forms a hydrogen bond with the 39 hydroxyl group of ribose, and the main chain NH group of C175 ECL2 interacts with the b-phosphate group. Disruption of this labile disulphide bond, for example, as possible in the complex with antagonist AZD1283, would also prevent such a bidentate coordination system of the nucleoside. The active metabolites of the thienopyridine drugs are also predicted to destabilize interactions of the P2Y 12 R with the nucleotide agonist by binding covalently to C97 3.25 . Mutation of either of these cysteine residues to alanine greatly reduces agonist binding (Extended Data Table 2 ), although it is known that the P2Y 12 R does not require this disulphide bond for overall structural integrity, that is, in the AZD1283 complex.
The action of nucleoside 59-triphosphate derivatives at P2Y 12 R, that is, agonism versus antagonism, has long been unclear. Although ATP and 2MeSATP were thought to be antagonists under physiological conditions 25 , the close conformational similarity between the 2MeSADP and 2MeSATP complexes suggests that ATP derivatives potentially qualify for similar signalling properties at P2Y 12 R as ADP derivatives, which is also supported by recent pharmacological data 3 . Moreover, AR-C66096, a non-cleavable triphosphate mimic that could be docked into the P2Y 12 R in an identical binding mode to 2MeSADP and 2MeSATP, displays characteristics of a partial agonist inhibiting cAMP production in CHO cells overexpressing P2Y 12 R (Extended Data Fig. 6 ). Of course, we emphasize that partial agonist activity of ATP derivatives may be expression-level dependent 26 . The 2MeSADP binding cavity appears to accommodate a number of other nucleotide ligands that mimic a triphosphate chain, including 
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AR-C67085 and cangrelor 27 (Extended Data Figs 7 and 8) . However, the nucleoside antagonist ticagrelor does not dock with a similar conformation to 2MeSADP in the P2Y 12 R because of the bulky N 6 substituent, unless a helical rearrangement occurs, particularly in helix VI. This docking observation suggests that reduction of agonist efficacy of these ligands is likely facilitated by N 6 substitutions in the nucleoside scaffold 27 . Consistently, we have shown that non-nucleotides AZD1283 and ticagrelor behave as competitive P2Y 12 R antagonists. Thus, we predict that the ligand-bound receptor conformations and consequently pharmacology of nucleotide-mimetic and non-nucleotide antagonists will be divergent.
These structural and pharmacological findings provide unexpected insights into the mechanism of agonist and antagonist interactions with P2Y 12 R, as schematically illustrated in Fig. 4 . As the agonist-bound pocket is sealed by a 'lid' formed by unusually cationic ECLs and the N terminus, agonist access to the binding pocket of apo P2Y 12 R would require plasticity of this extracellular region. Closing of the pocket in the absence of charged phosphates would also be disfavoured by electrostatic repulsion, with ,7 arginine and lysine side chains pointing towards the pocket. Binding of a nucleotide agonist like 2MeSADP involves stabilization of an inward position of helices VI and VII and formation of the lid, which is stabilized by numerous electrostatic interactions with the agonist phosphate groups. The additional phosphate group of 2MeSATP is also accommodated by a similar conformation of the lid, although distinct interactions may still affect the 2MeSATP binding and signalling profile. In stark contrast, an open extracellular side conformation is defined by binding of non-nucleotide antagonists like AZD1283, which keeps helices VI and VII away from the pocket and destabilizes the lid.
In conclusion, P2Y 12 R is the first receptor to demonstrate striking rearrangements in the extracellular regions, characterized by open and closed access to the ligand binding pocket. Whether such high plasticity of the binding pocket has evolved to enable optimal and specific recognition of negatively charged nucleotide ligands of the P2YR family, or is a more general feature of the d-group of class A GPCRs is currently unknown. Additional structures will help us to understand similarities and differences in ligand binding and receptor activation of the d-group receptors.
METHODS SUMMARY
The human P2Y 12 R-BRIL fusion protein was purified by metal affinity chromatography and crystalized in lipidic cubic phase (LCP). The diffraction data were collected from 17 crystals (P2Y 12 R-2MeSADP) and 6 crystals (P2Y 12 R-2MeSATP) on the BL41XU beamline at the SPring8, Japan, using a 10 mm minibeam. The structure was solved by molecular replacement and refined in Refmac5 and Buster.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Purification of P2Y 12 R-BRIL protein and crystallization in lipidic cubic phase. P2Y 12 R-BRIL construction, expression and membrane preparation were performed using the same procedure as described in the companion manuscript 5 . In brief, the human P2Y 12 R was subcloned into a modified pFastBac1 vector, with thermostabilized BRIL (Protein Data Bank accession code 1M6T) inserted at ICL3 (T223-R224) and a D294 7.49 N mutation. The fusion protein was expressed using Bac-to-Bac Baculovirus Expression System (Invitrogen) in Spodoptera frugiperda (Sf9) cells for 48 h and membrane was washed repeatedly using hypotonic buffer with low and high salt.
Before solubilization, purified membranes were incubated with 20 mM corresponding ligand (2MeSADP or 2MeSATP obtained from Tocris) in the presence of 2 mg ml 21 iodoacetamide, and EDTA-free protease inhibitor cocktail (Roche) for 30 min. P2Y 12 R-BRIL was extracted from the membrane by adding n-dodecyl-b-Dmaltopyranoside (DDM, Affymetrix) and cholesteryl hemisuccinate (CHS, Sigma) to the membrane solution to a final concentration of 0.5% (w/v) and 0.1% (w/v), respectively, and stirring was continued at 4 uC for 2.5 h. The supernatant was isolated by centrifugation at 160,000g for 30 min, followed by incubation in TALON IMAC resin (Clontech) at 4 uC, overnight. The resin was washed with twenty column volumes of 50 mM HEPES, pH 7.5, 1 M NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, and 30 mM imidazole. The protein was eluted with 5 column volumes of 50 mM HEPES, pH 7.5, 1 M NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 270 mM imidazole and 50 mM corresponding ligand. After removing imidazole by using a PD MiniTrap G-25 column (GE Healthcare), ligand concentration was increased to 2 mM. The protein was then treated overnight with His-tagged PreScission protease (20 mg per 500 ml of expressed material) and Histagged PNGase F (20 mg per 500 ml of expressed material) to remove the carboxyterminal His-tag and deglycosylate the receptor. PreScission protease, PNGase F and the cleaved 103 His-tag were removed from the sample by passing the sample over Ni-NTA superflow resin (Qiagen). The protein was then concentrated to 30-40 mg ml 21 with a 100 kDa molecular mass cut-off concentrator (Millipore).
Protein sample was reconstituted into lipidic cubic phase (LCP) by mixing 40% of ,30 mg ml 21 protein with 60% lipid (10% (w/w) cholesterol, 90% (w/w) monoolein) 28 . Crystallization trials were performed using a syringe lipid mixer as previously described ) within 10 days. Crystals were collected directly from LCP using 50-150 mm micromounts (M2-L19-50/150, MiTeGen) and flash frozen in liquid nitrogen. Data collection, structure solution and refinement. X-ray diffraction data were collected at the SPring-8 beam line 41XU, Hyogo, Japan, using a Rayonix MX225HE detector (X-ray wavelength 1.0000 Å ). The crystals were exposed with a 10 mm minibeam for 1 s and 1u oscillation per frame, and a rastering system was used to find the best diffracting parts of single crystals 30 . Most crystals of P2Y 12 R in complex with 2MeSADP diffracted to 3.0-2.5 Å resolution. XDS 31 was used for integrating and scaling data from 17 best-diffracting crystals for P2Y 12 R-2MeSADP complexes and 6 crystals for P2Y 12 R-2MeSATP complexes. The P2Y 12 R-2MeSADP complex was solved by molecular replacement with Phaser 32 using the receptor portion of PAR1 (PDB: 3VW7), converted to polyalanines, and BRIL (PDB: 1M6T) as initial models and refined in Refmac5 33 and Buster
34
. The P2Y 12 R-2MeSATP structure was solved using P2Y 12 R in complex with 2MeSADP and BRIL (PDB: 1M6T) as starting models and refined under the same procedure. Ligand-binding assays. Wild-type (WT) and mutant human P2Y 12 R plasmids with single amino acid substitutions were cloned into pcDNA3.0 vector and transfected into COS7 cells using Lipofectamine 2000 (Life Technologies). Cells were collected 48 h after transfection. After collection, cells were homogenized for 15 s and then centrifuged for 10 min at 1,000g. The suspension was re-centrifuged at 20,000g for 60 min. The resulting pellet was resuspended, homogenized, split into aliquots and maintained at -80 uC in a freezer until use. Protein concentrations were measured using Bio-Rad protein assay reagents.
For saturation experiments, 50 ml [ (10 nM) at 25 uC for 30 min. ADP, 2MeSADP and 2MeSATP were obtained from Sigma. AR-C66096 (.98%) was obtained from Tocris. The reaction was terminated by filtration with a 24-channnel Brandel cell harvester (Brandel) and washed twice with 5 ml cold Tris?HCl buffer containing 10 mM MgCl 2 . Radioactivity was measured using a scintillation counter (Tri-Carb 2810TR). Data were analysed using Prism 6 (GraphPad). Cyclic AMP (cAMP) accumulation assay. CHO cells stably expressing the human P2Y 12 R were plated in 96-well plates in 0.1 ml medium. After overnight incubation, the medium was removed, and cells were washed three times with 0.1 ml Hank's buffer, pH 7.4. Cells were then treated with the antagonists in the presence of rolipram (10 mM) for 20 min before the addition of agonists. Nucleotide derivatives were incubated with cells for 15 min followed by the addition of forskolin (10 mM) and incubation for another 15 min. The reaction was terminated by removing the supernatant, and cells were lysed upon the addition of 100 ml of 0.3% Tween-20. For determination of cAMP production, the ALPHA Screen cAMP assay kit (PerkinElmer) was used following the instructions provided with the kit. Docking. The P2Y 12 R-2MeSADP structure was prepared using the Protein Preparation Wizard tool implemented in the Schrödinger suite 35 , adding all the hydrogen atoms and the missing side chains of residues whose backbone coordinates were observed in the structure. The BRIL portion was removed. The orientation of polar hydrogens was optimized, the protein protonation states were adjusted and the overall structure was minimized with harmonic restraints on the heavy atoms, to remove strain. Then, all the hetero groups and water molecules were deleted.
The SiteMap tool of the Schrödinger suite was used to identify potential binding sites in the structure. Molecular docking of selected compounds (ADP, 2MeSADP, ATP, 2MeSATP, AR-C67085, AR-C66096, cangrelor and ticagrelor) at the P2Y 12 R structure was performed by means of the Glide package from the Schrödinger suite. In particular, a Glide Grid was centred on the centroid of residues located within 6 Å from the previously identified cavity. The Glide Grid was built using an inner box (ligand diameter midpoint box) of 14 Å 3 14 Å 3 14 Å and an outer box that extended 10 Å in each direction from the inner one (so that ligands up to 20 Å could be docked). Docking of ligands was performed in the rigid binding site using the XP (extra precision) procedure. The top scoring docking conformations for each ligand were subjected to visual inspection and analysis of protein-ligand interactions to select the final binding conformations in agreement with the experimental data. DNA sequence of the crystallization construct. The sequence was : ATGAAGACG  ATCATCGCCCTGAGCTACATCTTCTGCCTGGTGTTCGCCGACTACAAGG  ACGATGATGACGGCGCGCCGCAAGCCGTGGACAACCTCACATCAGCCC  CTGGCAACACCTCCCTCTGTACCCGCGACTACAAGATCACACAAGTTCT  CTTCCCCCTCCTCTACACAGTGTTGTTCTTCGTCGGCCTCATCACCAACG  GATTGGCTATGCGTATCTTCTTCCAGATCCGCTCCAAGTCTAACTTCATC  ATCTTCCTGAAGAACACTGTGATCTCGGACCTGCTCATGATCCTCACAT  TCCCATTCAAGATCCTGTCAGATGCCAAGCTCGGTACTGGCCCGTTGCG  TACATTCGTCTGCCAGGTTACCTCTGTGATCTTCTACTTCACTATGTACA  TCAGCATCTCATTCCTGGGTCTCATCACCATCGACAGGTACCAAAAGAC  CACTAGACCCTTCAAGACTAGCAACCCTAAGAACTTGCTGGGCGCTAAG  ATCCTGAGCGTGGTCATCTGGGCCTTCATGTTCCTCTTGTCACTGCCCAA  CATGATCCTCACCAACAGGCAGCCTAGAGATAAGAACGTGAAGAAGTG  TTCATTCCTCAAGTCGGAGTTCGGATTGGTTTGGCACGAAATCGTGAAC  TACATCTGCCAAGTCATCTTCTGGATCAACTTCCTGATCGTTATCGTGTG  TTACACATTGATCACCAAGGAGCTCTACAGGTCCTACGTCCGTACTGCT  GATCTGGAAGACAATTGGGAAACTCTGAACGACAATCTCAAGGTGATC  GAGAAGGCTGACAATGCTGCACAAGTCAAAGACGCTCTGACCAAGATG  AGGGCAGCAGCCCTGGACGCTCAGAAGGCCACTCCACCTAAGCTCGAG  GACAAGAGCCCAGATAGCCCTGAAATGAAAGACTTTCGGCATGGATTC  GACATTCTGGTGGGACAGATTGATGATGCACTCAAGCTGGCCAATGAA  GGGAAAGTCAAGGAAGCACAAGCAGCCGCTGAGCAGCTGAAGACCACC  CGGAATGCATACATTCAGAAGTACCTGCGCGGAGTCGGCAAGGTTCCTA  GGAAGAAGGTCAACGTTAAGGTGTTCATCATCATCGCTGTCTTCTTCAT  CTGCTTCGTTCCATTCCACTTCGCCCGTATCCCGTACACTTTGTCCCAAA  CACGCGACGTGTTCGATTGTACCGCTGAGAACACTCTGTTCTACGTCAA  GGAATCCACATTGTGGCTGACCTCTCTGAACGCCTGCCTCAACCCATTC  ATCTACTTCTTCCTCTGTAAGTCTTTCCGCAACTCGTTGATCTCCATGCT  GAAGTGCCCTAACTCTGCTACCAGCCTGTCCCAAGATAACAGAAAGAAG  GAGCAGGACGGAGGCGACCCGAACGAGGAAACCCCGATGGGCCGGCCT  CTGGAAGTTCTGTTCCAGGGGCCCCATCATCATCATCATCATCATCATCA  TCATTAG. 
